UK markets close in 4 hours 57 minutes

Valbiotis SA (ALVAL.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
5.98-0.18 (-2.92%)
As of 10:54AM CEST. Market open.
Full screen
Previous close6.16
Open6.16
Bid0.00 x 0
Ask0.00 x 0
Day's range5.98 - 6.16
52-week range4.01 - 7.45
Volume2,327
Avg. volume8,416
Market cap58.124M
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor

    LA ROCHELLE, France, June 13, 2022--Regulatory News: Valbiotis (FR0013254851 - ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the major success of the Phase II HEART clinical study, which achieved its objective of reducing blood LDL cholesterol level (primary endpoint) with TOTUM•070 and confirmed the very good tolerance of this active substance. This multicentric, randomized, placebo-cont

  • Business Wire

    Valbiotis Announces the Release of the Universal Registration Document

    LA ROCHELLE, France, May 19, 2022--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / PME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that its Universal Registration Document was filed to the French Financial Markets Regulator (AMF) May 19, 2022.

  • Business Wire

    Valbiotis - Combined Shareholders General Meeting Held on May 5, 2022

    LA ROCHELLE, France, May 06, 2022--Regulatory News: Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA / PME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its Combined Shareholders Meeting was held on May 5, 2022 at Espace Encan, La Rochelle, under the chairmanship of Sébastien PELTIER, Chairman of the Board of Directors, and that all the resolutions submitted for voting have been adopted by its shareho